Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Specimen Collection Study Protocol
- Conditions
- Focus in on Collecting Paired Specimens for Matrix Equivalency
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Biomerica
- Target Recruit Count
- 47
- Registration Number
- NCT04468386
- Locations
- 🇺🇸
Biomerica, Inc., Irvine, California, United States
Endpoint Determination Study Protocol
- Conditions
- Irritable Bowel Syndrome
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Biomerica
- Target Recruit Count
- 556
- Registration Number
- NCT03459482
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Family Medicine Specialists, Wauconda, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Specimen Collection Study for H. Pylori Testing
- Conditions
- Helicobacter Infections
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Biomerica
- Target Recruit Count
- 98
- Registration Number
- NCT02970110
- Locations
- 🇺🇸
Del Sol Research Management, Inc., Tucson, Arizona, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸Medley Research Associates, Medley, Florida, United States
News
Biomerica Appoints Scott Madel as Chief Commercial Officer to Drive inFoods IBS Test Commercialization
Biomerica has appointed Scott Madel as Chief Commercial Officer to accelerate commercialization of its inFoods IBS diagnostic test, bringing over 20 years of experience in laboratory testing and clinical diagnostics.
Biomerica Secures EU IVDR Certification for Food Intolerance Diagnostics Targeting IBD Patients
Biomerica achieved CE-marking under the European Union's In Vitro Diagnostic Medical Devices Regulation (IVDR) for its food intolerance products designed for Crohn's Disease and Ulcerative Colitis patients.
Biomerica's inFoods IBS Test Shows Significant Pain Reduction in Clinical Trial, Particularly Effective for IBS-C and IBS-M Patients
• Clinical trial results reveal inFoods IBS test achieved 59.6% success rate in reducing abdominal pain through targeted food elimination, compared to 42.2% in control group. • The test demonstrated exceptional efficacy in IBS-C and IBS-M subtypes, with 67.1% and 66% of patients respectively meeting FDA pain reduction targets. • Novel IBS-specific IgG antibody test enables precision nutrition approach by identifying individual trigger foods, requiring elimination of only 2-4 foods on average.
Biomerica's Fortel PSA Test Approved in UAE for Early Prostate Cancer Detection
Biomerica's Fortel PSA test has received approval from the UAE Ministry of Health and Prevention (MOHAP) for early prostate cancer detection.